Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Cancer. 2014 Sep 9;121(2):226–233. doi: 10.1002/cncr.29023

Table 3.

CSF and Serum Rituximab Levels (n=8)

Patient Pre* (ng/ml) Post (ng/ml) CSF (ng/ml) CSF/Post (%)
15 -- 410,000 343 0.084
21 36,400 375,000 498 0.133
22 47,500 367,000 351 0.096
25 < 500 334,000 276 0.083
26 -- 373,000 440 0.118
27 31,400 394,000 < 250** not calculated+
28 -- 649,000 272 0.042
30 36,900 349,000 1310 0.375
*

Levels detected in “Pre” serum samples likely from previous treatment with rituximab

**

Level was less than minimum detectable limit

+

Not calculated given that CSF level was less than detectable limit